AptarGroup, Inc.(ATR) Stock Research - Grey Stern Research

AptarGroup, Inc. (ATR) Stock Analysis

$159.07 (-0.48%)

ATR Financial Performance


Use the table below to view AptarGroup, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $159.07 -
52 Week Low $128.05 -
52 Week High $178.03 -
Market Cap $10.6 Billion 4/13
Gross Margin -41% 13/13
Profit Margin 11% 5/13
EBITDA margin 182% 1/13
Q3 - 2024 Revenue $909.3 Million 3/13
Q3 - 2024 Earnings $100.0 Million 5/13
Q3 - 2024 Free Cash Flow $153.8 Million 4/13
Trailing 4 Quarters Revenue $3.6 Billion 2/13
Trailing 4 Quarters Earnings $336.0 Million 4/13
Quarterly Earnings Growth 19% 5/13
Annual Earnings Growth 1% 5/13
Quarterly Revenue Growth 2% 8/13
Annual Revenue Growth 0% 9/13
Cash On Hand $325.5 Million 5/13
Short Term Debt $30.3 Million 5/13
Long Term Debt $822.7 Million 6/13

AptarGroup, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare AptarGroup, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 31.51 7/13
PS 2.96 7/13
PB 4.15 6/13
PC 32.52 6/13
Liabilities to Equity 0.81 4/13
ROA 0.07 3/13
ROE 0.13 4/13
Current Ratio 2.23 10/13
Quick Ratio 0.16 10/13
Long Term Debt to Equity 0.32 7/13
Debt to Equity 0.32 7/13
Burn Rate -5.47 10/13
Cash to Cap 0.03 8/13
CCR 1.54 5/13
EV to EBITDA 6.68 10/13
EV to Revenue 3.10 9/13

Company Details

AptarGroup, Inc. provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active material science solutions. The Beauty + Home segment primarily sells pumps, closures, aerosol valves, accessories, and sealing solutions to the personal care and home care markets; and pumps and decorative components to the beauty market. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves to the food and beverage markets. It sells its products through own sales force, as well as independent representatives and distributors in Asia, Europe, Latin America, and North America. The company has a strategic partnership with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene into dispensing applications; and a collaboration with Sonmol for developing a digital therapies and services platform targeting respiratory and other diseases. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.

CEO: Mr. Stephan Tanda

Website: https://www.aptar.com

Address: 265 Exchange Dr Ste 100 Crystal Lake, ILLINOIS

Exchange: New York Stock Exchange

Industry: Medical Instruments & Supplies

AptarGroup, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to AptarGroup, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
ResMed Inc. RMD $36.3 Billion
The Cooper Companies, Inc. COO $19.0 Billion
Haemonetics Corporation HAE $3.7 Billion
Teleflex Incorporated TFX $8.4 Billion
West Pharmaceutical Services, Inc. WST $25.2 Billion
Merit Medical Systems, Inc. MMSI $6.1 Billion
AngioDynamics, Inc. ANGO $488.0 Million
ICU Medical, Inc. ICUI $4.1 Billion
AtriCure, Inc. ATRC $1.9 Billion
Atrion Corporation ATRI $809.4 Million
Envista Holdings Corporation NVST $3.6 Billion
Akoya Biosciences, Inc. AKYA $159.1 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ATR Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 909.3 Million $100.0 Million
Q2 2024 $ 910.1 Million $90.5 Million
Q1 2024 $ 915.4 Million $83.1 Million
Q4 2023 $ 838.5 Million $62.4 Million
Q3 2023 $ 893.0 Million $84.3 Million
Q2 2023 $ 895.9 Million $83.1 Million
Q1 2023 $ 860.1 Million $54.8 Million
Q4 2022 $ 795.9 Million $59.0 Million

View All

ATR Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $325.5 Million $4.6 Billion $822.7 Million $2.6 Billion
Q2 2024 $221.5 Million $4.5 Billion $1.1 Billion $2.4 Billion
Q1 2024 $199.8 Million $4.4 Billion $1.2 Billion $2.4 Billion
Q4 2023 $223.6 Million $4.5 Billion $1.2 Billion $2.3 Billion
Q3 2023 $151.6 Million $4.3 Billion $1.2 Billion $2.2 Billion
Q2 2023 $121.0 Million $4.3 Billion $1.2 Billion $2.2 Billion
Q1 2023 $126.8 Million $4.3 Billion $1.2 Billion $2.1 Billion
Q4 2022 $141.7 Million $4.2 Billion $1.2 Billion $2.1 Billion

View All

ATR Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $153.8 Million -$54.0 Million $173.5 Million
Q2 2024 $75.4 Million -$68.2 Million $21.7 Million
Q1 2024 $16.7 Million -$75.7 Million -$24.3 Million
Q4 2023 $136.1 Million -$83.6 Million $72.1 Million
Q3 2023 $147.0 Million $0 $147.0 Million
Q2 2023 $125.9 Million $0 $125.9 Million
Q1 2023 $19.8 Million -$78.5 Million -$14.9 Million
Q4 2022 $88.0 Million -$84.3 Million $16.9 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions